SEC Form 3 · accession 0000899243-19-003179
Egalet Corp · EGLT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Iroko Pharmaceuticals Inc.
10% Owner
CRG Partners III L.P.
10% Owner
Capital Royalty L.P.
10% Owner
Iroko Properties Inc.
10% Owner
Period of report
Jan 31, 2019
Accepted (ET)
Feb 11, 2019 · 5:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001586105
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | holding | — | — | — | 4,586,874 | I | By Iroko Properties Inc. |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| WarrantsF1,F2 | $0.001 | holding | — | — | — | — | — | Common Stock | 2,436,459 | — | I |
Explanation of responses
- F1The shares of Common Stock (the "Shares") and the Warrants are owned directly by Iroko Properties Inc., which is a wholly owned subsidiary of Iroko Pharmaceuticals Inc. CRG Partners III - Parallel Fund "B" (Cayman) L.P., CRG Partners III (Cayman) Lev AIV I L.P., CRG Partners III (Cayman) Unlev AIV I L.P., CRG Partners III L.P. and CRG Partners III - Parallel Fund "A" L.P. (collectively, the "Funds") collectively hold all of the issued and outstanding shares of Iroko Pharmaceuticals Inc. CR Group L.P. may be deemed to beneficially own the Shares and the Warrants by virtue of its position as the investment manager for the Funds. This Form 3 is filed jointly by Iroko Pharmaceuticals Inc., Iroko Properties Inc., CR Group L.P. and each of the Funds.
- F2Pursuant to the terms of the Warrants, Iroko Properties Inc. has the right to acquire up to 2,436,459 additional shares of Common Stock, provided however that, for a period of eighteen (18) months following the date of the issuance of the Warrants, Iroko Properties Inc.'s right to exercise the Warrants is restricted so that it does not hold more than 49% of the issued and outstanding shares of Common Stock of the Issuer. The Warrants do not have an expiration date.